PPA
RPRX icon

Parametric Portfolio Associates’s Royalty Pharma RPRX Stock Holding History

Parametric Portfolio Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$15.4M Buy
394,985
+25,306
+7% +$994K 0.01% 1111
2021
Q4 		$14.7M Buy
369,679
+54,031
+17% +$2.1M 0.01% 1143
2021
Q3 		$11.4M Buy
315,648
+76,131
+32% +$2.96M 0.01% 1265
2021
Q2 		$9.82M Buy
239,517
+55,889
+30% +$2.38M 0.01% 1409
2021
Q1 		$8.01M Buy
183,628
+5,578
+3% +$264K ﹤0.01% 1838
2020
Q4 		$8.91M Buy
178,050
+158,211
+797% +$6.71M 0.01% 1657
2020
Q3 		$835K Buy
+19,839
New +$851K ﹤0.01% 3030

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parametric Portfolio Associates's RPRX Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Royalty Pharma (RPRX) stake by 6.8% in Q1 2022, buying an estimated $994K and bringing the position to 394,985 shares worth $15.4M. The position accounts for 0.01% of the portfolio, ranked #1111.

Parametric Portfolio Associates first reported a position in RPRX in Q3 2020 and has held it in 7 quarters since. 279 funds tracked by Wall St. Rank hold RPRX as of Q1 2022.

  • Parametric Portfolio Associates held 394,985 shares of Royalty Pharma worth $15.4M as of Q1 2022.
  • Parametric Portfolio Associates bought 25,306 Royalty Pharma shares in Q1 2022, an estimated $994K.
  • Royalty Pharma made up 0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1111 holding.
  • Parametric Portfolio Associates first reported a position in Royalty Pharma in Q3 2020 and has held it in 7 quarters since.
  • 279 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.